Aim: Identification of ALK fusions in non-small cell lung cancer (NSCLC) is key to determining eligibility for treatment with ALK inhibitors that markedly improve patients’ quality of life and survival outcomes. Here, ALK is linked to non-small cell lung carcinoma.